Records containing: Systemic Lupus Erythematosus

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2026-04-13
An Open-label, Multicenter, Dose Escalation, First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered RO7507062 in Participants With Systemic Lupus Erythematosus
CLINICAL_TRIALS study record update · 2026-04-09
A Phase 1/2, Open-label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Systemic Lupus Erythematosus
CLINICAL_TRIALS study record update · 2026-04-08
International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus
CLINICAL_TRIALS study record update · 2026-04-08
A Clinical Study to Evaluate the Safety and Efficacy of CHT105, an Allogeneic CAR-T Cell Injection Targeting CD19 and CD70, in Patients With Refractory Lupus Nephritis
CLINICAL_TRIALS study record update · 2026-04-07
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose Response Study to Evaluate the Efficacy and Safety of E6742 in Subjects With Systemic Lupus Erythematosus
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2026-04-06
Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE)
CLINICAL_TRIALS study record update · 2026-04-06
Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
CLINICAL_TRIALS study record update · 2026-04-06
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
CLINICAL_TRIALS study record update · 2026-04-06
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of IV Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Moderate to Severe Active Systemic Lupus Erythematosus While on Background Standard of Care Therapy
CLINICAL_TRIALS study record update · 2026-04-06
A Phase 1 Open-label, Multiregional, Multicenter, Basket Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy in Participants With Refractory Autoimmune Diseases
CLINICAL_TRIALS study record update · 2026-04-06
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus
CLINICAL_TRIALS study record update · 2026-04-06
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety of Obinutuzumab in Patients With Systemic Lupus Erythematosus
CLINICAL_TRIALS study record update · 2026-04-03
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus
CLINICAL_TRIALS study record update · 2026-04-03
A Phase1b, Multiple Ascending Dose, Open-label, Non-randomized Study Evaluating the Pharmacokinetics, Safety, and Efficacy of ABBV-319 in Subjects With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
CLINICAL_TRIALS study record update · 2026-04-03
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
CLINICAL_TRIALS study record update · 2026-04-03
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Clinical Trial Evaluating the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus
CLINICAL_TRIALS study record update · 2026-04-01
A First-in-Human, Phase 1, Open-Label, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CPTX2309 by Intravenous Administration in Healthy Volunteers and Subjects With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)
CLINICAL_TRIALS study record update · 2026-04-01
A Dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-1045 in Participants With Systemic Lupus Erythematosus and Rheumatoid Arthritis
CLINICAL_TRIALS study record update · 2026-03-27
A Phase 1b Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Budoprutug (TNT119) in Adult Subjects With Systemic Lupus Erythematosus (SLE)
CLINICAL_TRIALS study record update · 2026-03-27
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study
CLINICAL_TRIALS study record update · 2026-03-27
Prospective Observational Study About Pregnancy and Medically Assisted Conception in Rare Diseases
CLINICAL_TRIALS study record update · 2026-03-25
Impact of Therapeutic Drug Monitoring of Mycophenolate Mofetil in Patients With Lupus Nephritis: A Randomized Clinical Trial
CLINICAL_TRIALS study record update · 2026-03-24
Respiratory Function, Functional Capacity, Physical Activity, and Fatigue in Patients With Systemic Lupus Erythematosus: A Cross-Sectional Study
CLINICAL_TRIALS study record update · 2026-03-23
An Open-label, Multi-center, Phase 1/2 Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Participants With Severe, Refractory Systemic Lupus Erythematosus
CLINICAL_TRIALS study record update · 2026-03-20
A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)